Alert: Federal Agencies Announce Coordinated Support for Psychedelics Research and Development

Today marks a significant federal push for psychedelics, with the FDA finalizing guidance for clinical investigations and scheduling a public hearing on therapeutic use. HHS and VA have signed a 5-year MOU to accelerate research, clinical development, and responsible deployment of psychedelic drugs for veterans. Additionally, NIDA and ARPA-H are funding and promoting ibogaine research, indicating a broad, coordinated effort that will shape the regulatory and commercial landscape for psychedelic medicines.